{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T21:10:29Z","timestamp":1787605829673,"version":"build-2736575974"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,2]],"date-time":"2022-01-02T00:00:00Z","timestamp":1641081600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["20MC1920100"],"award-info":[{"award-number":["20MC1920100"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["21Y11901200"],"award-info":[{"award-number":["21Y11901200"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008750","name":"Shanghai Hospital Development Center","doi-asserted-by":"publisher","award":["SHDC2020CR4005"],"award-info":[{"award-number":["SHDC2020CR4005"]}],"id":[{"id":"10.13039\/501100008750","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ijid.2022.01.001","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T11:21:10Z","timestamp":1641468070000},"page":"147-150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Pharmacokinetic features of dolutegravir with rifampicin and rifabutin among patients coinfected with human immunodeficiency virus and tuberculosis\/mycobacterium avium complex"],"prefix":"10.1016","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3295-8702","authenticated-orcid":false,"given":"Xiaoqin","family":"Le","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoye","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinzhong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangrong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tangkai","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renfang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3850-4875","authenticated-orcid":false,"given":"Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2022.01.001_bib0001","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1056\/NEJMoa1014181","article-title":"Integration of antiretroviral therapy with tuberculosis treatment","volume":"365","author":"Abdool Karim","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2022.01.001_bib0002","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1093\/jac\/dkz217","article-title":"Population pharmacokinetics of dolutegravir: influence of drug\u2013drug interactions in a real-life setting","volume":"74","author":"Barcelo","year":"2019","journal-title":"J Antimicrob Chemoth"},{"key":"10.1016\/j.ijid.2022.01.001_bib0003","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00003088-200140050-00002","article-title":"Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials","volume":"40","author":"Burman","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijid.2022.01.001_bib0004","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1097\/QAI.0000000000002352","article-title":"Dosing of dolutegravir in tb\/hiv coinfected patients on rifampicin: twice is (always) better than once","volume":"84","author":"Cattaneo","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijid.2022.01.001_bib0005","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s40262-013-0093-2","article-title":"Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir","volume":"52","author":"Cottrell","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijid.2022.01.001_bib0006","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/cid\/ciz256","article-title":"Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: a multicenter, noncomparative, open-label, randomized trial","volume":"70","author":"Dooley","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.01.001_bib0007","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/QAI.0b013e318276cda9","article-title":"Safety, tolerability, and pharmacokinetics of the hiv integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects","volume":"62","author":"Dooley","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijid.2022.01.001_bib0008","series-title":"Eacs guidelines Version 11.0","year":"2021"},{"key":"10.1016\/j.ijid.2022.01.001_bib0009","doi-asserted-by":"crossref","first-page":"ofz174","DOI":"10.1093\/ofid\/ofz174","article-title":"Dolutegravir cerebrospinal fluid diffusion in hiv-1\u2013infected patients with central nervous system impairment","volume":"6","author":"Gel\u00e9","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijid.2022.01.001_bib0010","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAI.0b013e31829ed7a4","article-title":"Dolutegravir pharmacokinetics in the genital tract and colorectum of hiv-negative men after single and multiple dosing","volume":"64","author":"Greener","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijid.2022.01.001_bib0011","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1128\/AAC.00842-09","article-title":"Pharmacokinetics and safety of s\/gsk1349572, a next-generation hiv integrase inhibitor, in healthy volunteers","volume":"54","author":"Min","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2022.01.001_bib0012","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/QAI.0000000000002126","article-title":"Clinical and virological outcomes of tb\/hiv coinfected patients treated with dolutegravir-based hiv antiretroviral regimens: programmatic experience from botswana","volume":"82","author":"Modongo","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijid.2022.01.001_bib0013","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijantimicag.2019.04.009","article-title":"Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin","volume":"54","author":"Wang","year":"2019","journal-title":"Int J Antimicrob Ag"},{"key":"10.1016\/j.ijid.2022.01.001_bib0014","doi-asserted-by":"crossref","first-page":"e7532","DOI":"10.1016\/j.heliyon.2021.e07532","article-title":"Simultaneous determination of first-line anti-tuberculosis drugs and one metabolite of isoniazid by liquid chromatography\/tandem mass spectrometry in patients with human immunodeficiency virus-tuberculosis coinfection","volume":"7","author":"Xing","year":"2021","journal-title":"Heliyon"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222000029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222000029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:06:57Z","timestamp":1761120417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971222000029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":14,"alternative-id":["S1201971222000029"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2022.01.001","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic features of dolutegravir with rifampicin and rifabutin among patients coinfected with human immunodeficiency virus and tuberculosis\/mycobacterium avium complex","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2022.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}